SBIR grant from the NIAID (NIH) to investigate COVID-19-impacted type 2 diabetes
September 7, 2022
GlycoMantra has been awarded a two-year SBIR grant from the NIAID (NIH) to investigate COVID-19-impacted…
GlycoMantra received a SBIR Phase 1 grant from the NIDDK (NIH)
June 3, 2020
GlycoMantra received a SBIR Phase 1 grant from the NIDDK (NIH) June 03, 2020 GlycoMantra…
GlycoMantra will present at the Oncology Investor Conference.
March 25, 2020
GlycoMantra will present at the Oncology Investor Conference. GlycoMantra has been selected to pitch at the…
Glycomantra Will Present At RESI Europe
March 12, 2020
GlycoMantra has been selected to pitch in the Featured Company Pitch Session at RESI Europe meeting.